Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best healthcare stocks with the highest upside. Viking Therapeutics, Inc. (NASDAQ:VKTX) received a Buy rating from Oppenheimer’s Jay Olson on October 7, who assigned a $100 price target to the stock’s shares.

H.C. Wainwright analyst Joseph Pantginis also reiterated a bullish stance on Viking Therapeutics, Inc. (NASDAQ:VKTX) on September 22, giving the stock a Buy rating with a $102 price target.

The analyst supported the rating with Viking Therapeutics, Inc.’s (NASDAQ:VKTX) promising market position, stating that the company’s competitive efficacy and safety data from its oral and subcutaneous GLP-1 programs take the lead as its notable strengths.

He stated that these programs position Viking Therapeutics, Inc. (NASDAQ:VKTX) as a promising candidate for potential mergers and acquisitions while also reflecting the company’s strong pipeline.

Although Viking Therapeutics, Inc. (NASDAQ:VKTX) operates in a competitive landscape, Pantginis expressed optimism regarding its prospects, adding that the present debates associated with execution and competition fail to overshadow the strategic opportunities and potential growth that Viking Therapeutics, Inc. (NASDAQ:VKTX) presents. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage company that develops therapies for metabolic and endocrine disorders.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.